ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.89
+0.09 (+0.54%)
At close: 4:00PM EST

16.89 0.00 (0.00%)
After hours: 4:34PM EST

Stock chart is not supported by your current browser
Previous Close16.80
Open16.76
Bid15.15 x 3200
Ask17.05 x 800
Day's Range16.68 - 17.06
52 Week Range12.86 - 36.35
Volume616,811
Avg. Volume833,550
Market Cap803.26M
Beta (3Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-3.15
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.22
Trade prices are not sourced from all markets
  • Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%
    Zacks2 days ago

    Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%

    Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    # Acorda Therapeutics Inc ### NASDAQ/NGS:ACOR View full report here! ## Summary * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 9. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.33 billion over the last one-month into ETFs that hold ACOR are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
    Zacks3 days ago

    ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

    ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

  • Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
    Zacks3 days ago

    Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher

    Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    # Acorda Therapeutics Inc ### NASDAQ/NGS:ACOR View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 9. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding ACOR is favorable, with net inflows of $6.19 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
    Zacks7 days ago

    Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect

    Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.

  • Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
    Zacks8 days ago

    Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%

    Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    # Acorda Therapeutics Inc ### NASDAQ/NGS:ACOR View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Positive Short interest is moderate for ACOR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding ACOR is favorable, with net inflows of $5.99 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%
    Zacks10 days ago

    Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%

    Myriad Genetics (MYGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Business Wire10 days ago

    Acorda Provides 2018 Highlights and 2019 Guidance at J.P. Morgan Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) today provided 2018 highlights, 2019 guidance and commercialization plans for INBRIJA at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. “The approval of INBRIJA is a major milestone for Acorda. Burkhard Blank, M.D., Acorda’s Chief Medical Officer, added, “INBRIJA represents the first FDA approval of a treatment using the ARCUS® technology, a platform that allows delivery of relatively large doses of medication through inhalation.

  • Company News For Dec 26, 2018
    Zacks22 days ago

    Company News For Dec 26, 2018

    Companies In The News Are: AAPL,MB,TSLA,ACOR

  • Benzinga22 days ago

    Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James

    Acorda Therapeutics Inc (NASDAQ: ACOR ) announced FDA approval for its Parkinson's drug Inbrija Monday, boosting the stock in premarket trading. Not everyone is sold on the product’s prospects. The Analyst  ...

  • Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
    Zacks22 days ago

    Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

    It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.

  • ACCESSWIRE22 days ago

    Biotech News Driving These Companies

    HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently. We are highlighting: Endonovo Therapeutics, ...

  • Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today
    Motley Fool24 days ago

    Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today

    Even as the market fell again, these stocks posted gains. Find out why.

  • Biotech Stock Flies After FDA Approves Parkinson's Treatment
    Investor's Business Daily24 days ago

    Biotech Stock Flies After FDA Approves Parkinson's Treatment

    Acorda stock rocketed Monday after the FDAn approved its Parkinson's treatment, Inbrija, to treat symptoms during "off periods." Prescriptions will be available in the first quarter of 2019.

  • Bloomberg24 days ago

    Acorda Rises 9.7 Percent After FDA Gives Nod for Parkinson's Therapy

    The drug, which will be sold under the name Inbrija, is an inhaled version of levodopa, an existing therapy that treats the effects of the neurodegenerative disorder. Acorda declined to say how it plans to price the product, and an outside spokesman said Acorda was still in conversations with insurers and the price would be made public next year. Last year, the FDA refused to review the company’s application for the drug, issuing a “refusal to file letter” that said it hadn’t provided enough information about its manufacturing process.

  • Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
    Zacks24 days ago

    Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija

    Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.

  • MarketWatch24 days ago

    Acorda Therapeutics' Inbrija Parkinson's disease treatment gets FDA OK

    Acorda Therapeutics Inc. said Monday the Food and Drug Administration has approved its Inbrija treatment for off episodes in people with Parkinson's disease. The company said it expects the treatment to be available by prescription in the first quarter of 2019. "Despite being on treatment, patients may experience OFF periods as Parkinson's progresses, which can be disruptive," said Todd Sherer, chief executive of the Michael J. Fox Foundation. "We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control." Acorda's stock, which is still inactive in premarket trade, has lost 31% over the past three months, while the S&P 500 has declined 17%.

  • ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)
    Business Wire24 days ago

    ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low levels of dopamine between doses of oral carbidopa/levodopa, the standard oral baseline Parkinson’s treatment. “Today’s approval of INBRIJA marks a major milestone for both Acorda and the Parkinson’s community, for whom we are gratified to have developed this much needed therapy,” said Ron Cohen, M.D., Acorda President and CEO.

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit26 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire27 days ago

    Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low levels of dopamine between doses of oral carbidopa/levodopa, the standard oral baseline Parkinson’s treatment. “Today’s approval of INBRIJA marks a major milestone for both Acorda and the Parkinson’s community, for whom we are gratified to have developed this much needed therapy,” said Ron Cohen, M.D., Acorda President and CEO.

  • Business Wire29 days ago

    Acorda to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 at 8:00am PST / 5:00am EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder), an investigational inhaled formulation of levodopa for symptoms of OFF periods for people with Parkinson’s on a carbidopa/levodopa regimen, is under FDA review with a PDUFA date of January 5, 2019.

  • ACCESSWIRElast month

    Acorda Therapeutics PDUFA Date, Pipeline Review and Third Quarter Highlights

    NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Acorda Therapeutics, Inc. (ACOR), a company that develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder), an investigational inhaled formulation of levodopa for symptoms of OFF periods for people with Parkinson's on a carbidopa/levodopa regimen, is under FDA review. Acorda is preparing for the expected launch of Inbrija.

  • Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
    Insider Monkeylast month

    Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?

    The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]